Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Banknote Ban Boosts Business At India E-Pharmacy Start-Ups

Executive Summary

Other retailers may be feeling the pain, but India’s nascent e-pharmacy sector says business is better than ever since the country’s prime minister outlawed 86% of the cash in circulation to address tax avoidance.

You may also be interested in...



India Pharma 2017: 3Cs And D (Disruption)?

2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.

India Pharma 2017: 3Cs And D (Disruption)?

2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.

Will 'Businessman' Trump See The Value In Indian Generics?

The election of Donald Trump as the next US president might suggest a degree of policy unpredictability for pharma companies but Indian firms are hoping that the businessman in the real estate mogul and President-elect will see the value that generics offer.

Topics

UsernamePublicRestriction

Register

SC097755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel